BOCA RATON, Fla, June 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it ...
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to ...
MarketBeat on MSN
INmune Bio Q2 Earnings Call Highlights
INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom ...
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), which is under review for ...
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEB Literature review of 65 studies confirms and expands understanding of substantial ...
The last time I spoke about Abeona Therapeutics (ABEO), it was with a Seeking Alpha article entitled "Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn." With respect to ...
Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...
The possibility that blood stem cells from one individual can be permanently transplanted to another individual has been one of the most successful examples of experimental medicine. In hematopoietic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results